The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
Novo Nordisk and Vivani Medical are developing a semaglutide implant that could eliminate the need for weekly injections. Here is everything to know about the technology.
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
Often hailed as 'nature's Ozempic,' psyllium husk is a fiber-rich supplement gaining traction for its wide-ranging health benefits. But does it live up to the buzz? This article dives into the evidence for its impact on gut health, cholesterol, blood sugar, and weight management.
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
Discover how GLP-1 medications are transforming lives, offering significant weight loss and improved self-esteem. This article delves into the personal victories and the broader societal implications, including the persistent pressures on women's bodies.
The rise of GLP-1 agonists has sparked a global conversation about weight loss. This article delves into the cultural phenomenon, its psychological underpinnings, and how a new horror film, 'Saccharine,' offers a chilling commentary.
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
